About more than half of the drugs currently in use are chiral compounds and near 90% of the
last ones are marketed as racemates consisting of an equimolar mixture of two enantiomers …

Pharmacologically active compounds including both legally used pharmaceuticals and illicit
drugs are potent environmental contaminants. Extensive research has been undertaken …

Electrochemical asymmetric catalysis has emerged as a sustainable and promising
approach to the production of chiral compounds and the utilization of both the anode and …

The merger of electrochemistry and transition metal catalysis has emerged as a powerful
tool to join two electrophiles in an enantioselective manner. However, the development of …

A unique nickel/organic photoredox co‐catalyzed asymmetric reductive cross‐coupling
between α‐chloro esters and aryl iodides is developed. This cross‐electrophile coupling …

Nonsteroidal anti-inflammatory drug derivatives (NSAIDs) are an important class of
medications. Here we show a visible-light-promoted photoredox/nickel catalyzed approach …

The first iron-catalyzed enantioselective cross-coupling reaction between an organometallic
compound and an organic electrophile is reported. Synthetically versatile racemic α-chloro …

Optically active α-arylation carbonyl units are widely present in a wide variety of drugs,
bioactive natural products, and valuable pharmacologically active molecules. Catalytic …

The world is chiral. Most of the molecules in it are chiral, and asymmetric synthesis is an
important means by which enantiopure chiral molecules may be obtained for study and sale …

The first cobalt-catalyzed asymmetric Kumada cross-coupling with high enantioselectivity
has been developed. The reaction affords a unique strategy for the enantioselective …